Form 4: Boston Scientific CEO Michael Mahoney Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.
Summary
- Michael Mahoney, the Chairman, President, and CEO of Boston Scientific, executed stock options to acquire common stock and subsequently sold a portion of those shares.
- The transactions were conducted on October 7, 2024, under a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
- Mahoney exercised options to acquire 56,211 shares at $17.26 and 55,675 shares at $16.31.
- He then sold 80,692 shares at a weighted average price of $84.3127 and 82,085 shares at a weighted average price of $84.9416.
- Following these transactions, Mahoney directly owns 1,572,096 shares of common stock and indirectly owns 209,278 shares through a trust.
- He also holds options to purchase 224,846 shares at $17.26 and 55,676 shares at $16.31.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which is a normal course of business. There is no indication of positive or negative implications for the company's performance.
Positives
- The transactions were conducted under a pre-established 10b5-1 trading plan, which is generally viewed as a transparent and orderly way for insiders to manage their stock holdings.
Industry Context
Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market will likely view this as a routine transaction.
Comparison to Industry Standards
- Comparing Mahoney's transactions to other CEOs in the medical device industry, the use of a 10b5-1 plan is a common practice.
- For example, CEOs at Medtronic and Abbott also frequently use such plans for managing their stock holdings.
- The size of the transactions is within the typical range for executives at companies of Boston Scientific's size.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders, as they are part of a pre-planned trading strategy.
Key Dates
| Date | Description |
|---|---|
| 02/23/2016 | First anniversary of the date of grant for stock options vesting in four equal annual installments. |
| 02/22/2017 | First anniversary of the date of grant for stock options vesting in four equal annual installments. |
| 02/28/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 10/07/2024 | Date of the reported transactions (exercise of options and sale of shares). |
| 10/08/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.